[go: up one dir, main page]

PL2307007T3 - Modulatory receptora fosforanu sfingozyny 1 i ich zastosowanie do leczenia zapalenia mięśniowego - Google Patents

Modulatory receptora fosforanu sfingozyny 1 i ich zastosowanie do leczenia zapalenia mięśniowego

Info

Publication number
PL2307007T3
PL2307007T3 PL09780938T PL09780938T PL2307007T3 PL 2307007 T3 PL2307007 T3 PL 2307007T3 PL 09780938 T PL09780938 T PL 09780938T PL 09780938 T PL09780938 T PL 09780938T PL 2307007 T3 PL2307007 T3 PL 2307007T3
Authority
PL
Poland
Prior art keywords
sphingosine
receptor modulators
phosphate receptor
muscle inflammation
treat muscle
Prior art date
Application number
PL09780938T
Other languages
English (en)
Inventor
Syed Sohail Ahmed
Marco Londei
Timothy Wright
Peter Gergely
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40090418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2307007(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2307007T3 publication Critical patent/PL2307007T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL09780938T 2008-07-23 2009-07-22 Modulatory receptora fosforanu sfingozyny 1 i ich zastosowanie do leczenia zapalenia mięśniowego PL2307007T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08161005 2008-07-23
PCT/EP2009/059440 WO2010010127A1 (en) 2008-07-23 2009-07-22 Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
EP09780938.8A EP2307007B1 (en) 2008-07-23 2009-07-22 Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation

Publications (1)

Publication Number Publication Date
PL2307007T3 true PL2307007T3 (pl) 2015-03-31

Family

ID=40090418

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09780938T PL2307007T3 (pl) 2008-07-23 2009-07-22 Modulatory receptora fosforanu sfingozyny 1 i ich zastosowanie do leczenia zapalenia mięśniowego

Country Status (25)

Country Link
US (2) US9149459B2 (pl)
EP (2) EP2307007B1 (pl)
JP (2) JP5878015B2 (pl)
KR (2) KR101608108B1 (pl)
CN (1) CN102105144B (pl)
AU (1) AU2009273259B2 (pl)
BR (1) BRPI0916232A2 (pl)
CA (1) CA2730751A1 (pl)
CL (1) CL2011000138A1 (pl)
CY (1) CY1115662T1 (pl)
DK (1) DK2307007T3 (pl)
ES (1) ES2522345T3 (pl)
HK (1) HK1155096A1 (pl)
HR (1) HRP20141152T1 (pl)
IL (2) IL210550A (pl)
MA (1) MA32557B1 (pl)
MX (1) MX2011000881A (pl)
NZ (1) NZ590328A (pl)
PL (1) PL2307007T3 (pl)
PT (1) PT2307007E (pl)
RU (1) RU2521286C2 (pl)
SG (1) SG10201503157PA (pl)
SI (1) SI2307007T1 (pl)
WO (1) WO2010010127A1 (pl)
ZA (1) ZA201100166B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101618906B1 (ko) 2008-08-18 2016-05-09 노파르티스 아게 말초 신경병증의 치료를 위한 화합물
JO3619B1 (ar) 2011-01-07 2020-08-27 Novartis Ag صياغات مثبطة للمناعة
WO2012097330A2 (en) * 2011-01-14 2012-07-19 University Of Washington Compositions and methods for treating degenerative muscle conditions
FR3000959B1 (fr) 2013-01-14 2015-08-21 Holis Technologies Nouveaux intermediaires de synthese permettant d'acceder avec de bons rendements a des derives de sphingosines, ceramides et sphingomyelines
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
DK3311161T3 (da) * 2015-06-18 2021-06-14 Cytoo Fremgangsmåde til high-throughput og funktionel screening af muskelrelaterede lidelser og biologiske processer
WO2017120124A1 (en) 2016-01-04 2017-07-13 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
WO2022037525A1 (zh) * 2020-08-20 2022-02-24 南京明德新药研发有限公司 苯乙酮肟类化合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0749419B1 (de) * 1994-03-10 2001-10-24 Bayer Ag Oxim-derivate und ihre verwendung als schädlingsbekämpfungsmittel
AR035411A1 (es) 2000-12-29 2004-05-26 Fujisawa Pharmaceutical Co Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto
AU2002320470A1 (en) * 2001-07-11 2003-01-29 Musc Foundation For Research Development Modulators of ceramidase and methods of use based thereon
EP1469863A2 (en) 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
WO2003062252A1 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
TW200424187A (en) * 2003-04-04 2004-11-16 Hoffmann La Roche New oxime derivatives and their use as pharmaceutically active agents
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
AU2004240649A1 (en) * 2003-05-19 2004-12-02 Irm, Llc Immunosuppressant compounds and compositions
EP2644195A1 (en) * 2003-05-19 2013-10-02 Irm Llc Immunosuppressant Compounds and Compositions
WO2005077896A1 (en) * 2004-02-16 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments
UA74941C2 (en) 2004-04-26 2006-02-15 Fos Internat S A A metal-thermal process for producing magnesium and vacuum induction furnace for realizing the same
WO2005113330A1 (en) 2004-05-05 2005-12-01 Adler, Richard, S. Systems and methods for protecting ship from attack on the surface or under water
WO2006047195A2 (en) * 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
SG187468A1 (en) * 2004-11-29 2013-02-28 Novartis Ag Dosage regimen of an s1p receptor agonist
US7919519B2 (en) * 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
WO2008021532A2 (en) * 2006-08-17 2008-02-21 University Of Chicago Treatment of inflammatory diseases
EP2069318B1 (en) * 2006-09-21 2012-09-12 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
PE20090150A1 (es) * 2007-04-19 2009-05-08 Glaxo Group Ltd Compuestos derivados de oxadiazol
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
UY32350A (es) * 2008-12-22 2010-04-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p

Also Published As

Publication number Publication date
IL210550A (en) 2016-02-29
IL210550A0 (en) 2011-03-31
RU2011106356A (ru) 2012-08-27
KR101608108B1 (ko) 2016-03-31
CN102105144B (zh) 2013-11-13
US20110124620A1 (en) 2011-05-26
RU2521286C2 (ru) 2014-06-27
EP2695615A3 (en) 2014-04-30
ZA201100166B (en) 2011-09-28
HRP20141152T1 (hr) 2015-01-16
JP2015038100A (ja) 2015-02-26
KR20110031996A (ko) 2011-03-29
KR101624098B1 (ko) 2016-05-24
SI2307007T1 (sl) 2014-11-28
KR20160039694A (ko) 2016-04-11
AU2009273259B2 (en) 2013-05-02
SG10201503157PA (en) 2015-06-29
CY1115662T1 (el) 2017-01-25
NZ590328A (en) 2013-04-26
IL243612A0 (en) 2016-02-29
EP2307007B1 (en) 2014-08-27
PT2307007E (pt) 2014-11-13
JP5878015B2 (ja) 2016-03-08
CL2011000138A1 (es) 2011-07-01
CN102105144A (zh) 2011-06-22
US9149459B2 (en) 2015-10-06
US20160175282A1 (en) 2016-06-23
MX2011000881A (es) 2011-03-02
JP2011528695A (ja) 2011-11-24
DK2307007T3 (da) 2014-11-10
EP2307007A1 (en) 2011-04-13
BRPI0916232A2 (pt) 2017-08-29
EP2695615A2 (en) 2014-02-12
HK1155096A1 (en) 2012-05-11
CA2730751A1 (en) 2010-01-28
WO2010010127A1 (en) 2010-01-28
AU2009273259A1 (en) 2010-01-28
MA32557B1 (fr) 2011-08-01
ES2522345T3 (es) 2014-11-14

Similar Documents

Publication Publication Date Title
IL243612A0 (en) Modulators for the sphingosine 1 phosphate receptor and their use in the treatment of muscle infection
HUS2000038I1 (hu) Szfingozin foszfát receptor új modulátorai
HUS2000045I1 (hu) Szelektív szfingozin-1-foszfát receptor modulátorok és királis szintézis eljárások
HK1215281A1 (zh) 人骨骼肌中的褐色脂肪細胞祖細胞
EP2349321A4 (en) ANNEXIN AND ITS USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
IL219690A0 (en) Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
SI2137141T1 (sl) Arilamidi bifenil-4-il-sulfonske kisline in njihova uporaba kot terapevtska sredstva
IL209306A0 (en) Novel modulators of sphingosine phosphate receptors
IL207965A0 (en) N-substitutedbenzenepropanamide ofr denzenepropenamide derivatives for use in the treatment of pain and inflammation
GB2464927B (en) Apparatus and method for metering the use of electricity
EP2300044A4 (en) METHOD AND COMPOSITIONS FOR TREATING PAIN WITH OMEGA CONOTOXINES
TWI340035B (en) Lemnalol applying for treating inflammation and pain